Immunotherapy available for Childhood Leukaemia
Following a price deal between the NHS and Swiss drugs firm Novartis in September 2018, the drug Kymriah has now been made available for CAR-T Cell treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in paediatric and young adult patients. This offers hope for children who have exhausted all other treatment options.…